Dexcom (NASDAQ: DXCM) legal chief sells stock under 10b5-1 plan

Rhea-AI Filing Summary

DEXCOM INC executive Michael Jon Brown, EVP Chief Legal Compliance Officer, reported selling 1,700 shares of common stock on August 14, 2026 at $91.93 per share in an open-market transaction under a pre-arranged Rule 10b5-1 Plan. Following this sale, he directly holds 102,953 shares, including 74,753 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029.

Insider Trade Summary 10b5-1

Net Seller: 1,700 shares

Net Sell 1 txn

Insider Brown Michael Jon

Role EVP Chief Legal Compliance Off

Sold 1,700 shs ($156K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,700	$91.93	$156K

Holdings After Transaction: Common Stock — 102,953 shares (Direct)

Footnotes (2)

1. F1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
2. F2. Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Key Figures

Shares sold: 1,700 shares Sale price per share: $91.93 per share Shares held after transaction: 102,953 shares +5 more

8 metrics

Shares sold 1,700 shares Common stock sale on August 14, 2026 by Michael Jon Brown

Sale price per share $91.93 per share Price for the 1,700 Dexcom common shares sold on August 14, 2026

Shares held after transaction 102,953 shares Direct holdings of Michael Jon Brown following the August 14, 2026 sale

Unvested RSUs included in holdings 74,753 units Unvested restricted stock units included in the 102,953-share post-transaction balance

RSUs granted March 8, 2026 39,019 units Part of unvested RSUs scheduled to vest through March 8, 2029

RSUs granted March 8, 2025 (2028 tranche) 19,948 units Unvested RSUs vesting through March 8, 2028

RSUs granted March 8, 2025 (2027 tranche) 8,549 units Unvested RSUs vesting through March 8, 2027

RSUs granted March 8, 2024 7,237 units Unvested RSUs vesting through March 8, 2027

Key Terms

Rule 10b5-1 Plan, restricted stock units, unvested, open market or private transaction

4 terms

Rule 10b5-1 Plan regulatory

"This 10b5-1 Plan allows the orderly disposition of shares owned"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"Included in this number are 74,753 unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

unvested financial

"Included in this number are 74,753 unvested restricted stock units"

open market or private transaction market

"Sale in open market or private transaction"

FAQ

What insider transaction did DXCM executive Michael Jon Brown report?

Michael Jon Brown reported a sale of 1,700 shares of Dexcom common stock on August 14, 2026 at $91.93 per share. The transaction was described as a sale in the open market or a private transaction under a Rule 10b5-1 Plan.

How many DXCM shares does Michael Jon Brown hold after the reported sale?

After the transaction, Michael Jon Brown directly holds 102,953 Dexcom shares. This total includes 74,753 unvested restricted stock units that are scheduled to vest over several years, extending through March 8, 2029, subject to their grant terms.

Was the DXCM insider sale by Michael Jon Brown under a Rule 10b5-1 plan?

Yes. The filing states that Brown adopted a Rule 10b5-1 Plan on November 26, 2025, and the 1,700-share sale was executed pursuant to this plan. The plan is described as allowing the orderly disposition of his Dexcom shares.

What unvested restricted stock units does Michael Jon Brown have at DXCM?

Brown’s holdings include 74,753 unvested restricted stock units. These comprise grants on March 8, 2026, March 8, 2025, and March 8, 2024, with portions scheduled to vest through March 8, 2029, according to the vesting schedule disclosed.

What is the significance of the 10b5-1 plan mentioned in the DXCM Form 4?

The filing explains that Brown’s 10b5-1 Plan, adopted on November 26, 2025, permits the orderly disposition of his Dexcom shares. The August 14, 2026 sale of 1,700 shares was executed pursuant to this pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 04:08 PM Accepted by SEC EDGAR 08/17/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Michael Jon

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Chief Legal Compliance Off

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		S		1,700(1)	D	$91.93	102,953(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On November 26, 2025, Mr. Brown adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Brown. The shares set forth above were sold pursuant to the 10b5- 1 Plan.

2. Included in this number are 74,753 unvested restricted stock units, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 8,549 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)